Expression of Biologically Active Human TRAIL in Transgenic Pigs
- 27 July 2005
- journal article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 80 (2) , 222-230
- https://doi.org/10.1097/01.tp.0000164817.59006.c2
Abstract
Xenotransplantation of porcine organs into human recipients is a potential option for overcoming the dramatic shortage of suitable donor organs. To date, transgenic modification of pig organs has achieved partial or temporal reduction of xenograft rejection by inhibition of hyperacute rejection. Expression of human tumor necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL) in transgenic pigs might be a strategy for controlling posthyperacute rejection mechanisms mediated by cellular components of the immune system. The objective of this study was generation of a transgenic pig model to evaluate the potential of this strategy for xenotransplantation. Transgenic pigs were generated by microinjection of an expression vector for human TRAIL under control of the murine H-2K promoter. Expression of the transgene was analyzed by Western blot and immunohistochemistry. Biologic activity of TRAIL on transgenic porcine lymphocytes was evaluated in co-culture experiments using Jurkat and Hut 78.2 cells as targets. In three lines of transgenic pigs, human TRAIL protein was detected in the membrane fractions of various tissues. Highest expression levels were observed in spleen and lung. Human TRAIL expression on porcine lymphocytes was augmented on activation of cells. Transgenic pig lymphoblasts induced apoptosis in Jurkat and Hut 78.2 cells, which was inhibited by neutralizing anti-TRAIL antibodies, demonstrating a TRAIL-specific effect. Ubiquitous expression of human TRAIL was achieved in transgenic pigs without detrimental side effects. Pigs expressing biologically active human TRAIL will be used for future xenotransplantation experiments to modulate primate anti-pig cellular immune responses.Keywords
This publication has 50 references indexed in Scilit:
- Regulation of tumour necrosis factor‐related apoptosis‐inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophilsImmunology, 2004
- TRAIL/Apo-2-ligand-induced apoptosis in human T cellsEuropean Journal of Immunology, 1998
- The Novel Receptor TRAIL-R4 Induces NF-κB and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death DomainImmunity, 1997
- TRANSGENIC PIGS EXPRESSING HUMAN CD59 AND DECAY-ACCELERATING FACTOR PRODUCE AN INTRINSIC BARRIER TO COMPLEMENT-MEDIATED DAMAGE1Transplantation, 1997
- Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmACurrent Biology, 1996
- EXPRESSION OF FUNCTIONAL DECAY-ACCELERATING FACTOR (CD55) IN TRANSGENIC MICE PROTECTS AGAINST HUMAN COMPLEMENT-MEDIATED ATTACK1Transplantation, 1996
- A role for CD95 ligand in preventing graft rejectionNature, 1995
- Porcine aortic endothelial cells activate human T cells: Direct presentation of MHC antigens and costimulation by ligands for human CD2 and CD28Immunity, 1994
- Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor familyCell, 1993
- The regulation and expression of MHC class I genesImmunology Today, 1990